Dean Fennell
University of Leicester · Department of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX · Queen's University of Belfast
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dean Fennell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05455424 · Niraparib Efficacy in Patient With Unresectable MesotheliomaUniversity Hospital Southampton NHS Foundation Trust · completed · Mesothelioma, Malignant · principal investigator
- Ph2NCT03654833 · Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaUniversity of Leicester · completed · Mesothelioma, Malignant · study director
- Ph3NCT03063450 · CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaUniversity of Southampton · completed · Mesothelioma · principal investigator
- Ph1/Ph2NCT02758587 · Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NHS Greater Glasgow and Clyde · unknown · Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms · principal investigator
- Ph2NCT02139904 · Vinorelbine in MesotheliomaWales Cancer Trials Unit · completed · Mesothelioma · study chair
- Ph2NCT01788332 · Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)Lisette Nixon · unknown · Non-small Cell Lung Cancer · study chair
- Ph1/Ph2NCT01353482 · A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural MesotheliomaUniversity College, London · withdrawn · Malignant Pleural Mesothelioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:40 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- 339 citationsRCR 10.2
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol · 2021226 citationsRCR 12.4
- Ethnic variation in health and the determinants of health among Latinos.Soc Sci Med · 2005175 citationsRCR 6.6
- 168 citationsRCR 5.1
- 166 citationsRCR 4.6
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet Respir Med · 2019122 citationsRCR 4.8
- EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.Lancet Oncol · 2022119 citationsRCR 7.7
- 118 citationsRCR 4.0
- Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.Lancet Respir Med · 2024116 citationsRCR 18.1
- Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.Lancet Respir Med · 2021102 citationsRCR 4.8